Milella et al. reported a prospective phase II study in which patients were divided into four groups (EGFR mutation; highly polysomic/amplified EGFR; EGFR and/or pAKT positive; adenocarcinoma/BAC with a non-smoking history) and were given EGFR TKIs as second or subsequent line treatment. This evidence concerns the gene EGFR and adenocarcinoma.